Clinical Trial Update: Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction [Phase 3]

View source ↗

Summary

A Phase 3 study is exploring the effects of an angiotensin receptor/neprilysin inhibitor on transthyretin cardiac amyloidosis (ATTR-CM) and heart failure with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction
• Transthyretin Cardiac Amyloidosis

Drugs mentioned

• Sacubitril/Valsartan (sacubitril/valsartan)

Snippet

Sponsor: Puerta de Hierro University Hospital | Conditions: Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) | Phase 3 | Status: NOT_YET_RECRUITING